TuHURA Biosciences (NASDAQ:HURA) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead immune-priming candidate, IFx-2.0, for the treatment of stage IIB to stage IV cutaneous melanoma.
The stock rose as much as 20% in early trading following the news, providing a vital lift to the Tampa-based biotech as it navigates a critical Phase 3 registration trial.
The designation is supported by Phase 1 data published in Molecular Therapeutics, which confirmed that IFx-2.0 was safe with no serious dose-limiting toxicities.
More importantly for clinicians, the study found that patients who had previously failed or become refractory to anti-PD1 checkpoint inhibitors experienced renewed clinical benefits when rechallenged with immunotherapy following IFx-2.0 treatment.
The therapy works by injecting a bacterial protein gene directly into tumors, effectively "cloaking" them in a way that triggers the patient’s own immune system to recognize and attack the cancer.
The ODD status provides TuHURA with significant financial and strategic tailwinds, including seven years of market exclusivity upon potential approval, tax credits for clinical trial expenses, and a waiver of the multi-million dollar FDA user fee.
While the company is currently focused on its ongoing Phase 3 trial for Merkel Cell Carcinoma in combination with Keytruda®, CEO Dr. James Bianco noted that this new designation highlights the drug’s potential as a "universal" approach for advanced skin cancers.
The regulatory win comes at a pivotal time for TuHURA, which recently received a notice of non-compliance from Nasdaq regarding its minimum bid price and is looking to its late-stage pipeline to regain its footing in the 2026 market.